• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    XBiotech Inc. filed SEC Form 8-K: Leadership Update

    6/24/25 5:06:29 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XBIT alert in real time by email
    false 0001626878 0001626878 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    _____________________________________

     

    FORM 8-K

    _____________________________________

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 24, 2025

    _____________________________________

     

    XBIOTECH INC.
    (Exact name of Registrant as specified in its charter)

    _____________________________________

     

    British Columbia, Canada
    (State of Incorporation)
       
    001-37347
    (Commission File Number)

     

    N/A
    (I.R.S. Employer Identification No.)

     

    5217 Winnebago Ln, Austin, TX

    78744

    (Address of principal executive offices) (Zip Code)

     

    (512) 386-2900

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, no par value XBIT NASDAQ Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    XBiotech Inc. (“XBiotech” or the “Company”) announces the June 24, 2025 appointments of Dr. Thomas Kündig and Craig Rademaker to the Company’s Board of Directors. Dr. Kündig has further been appointed to serve on the Compensation Committee, while Mr. Rademaker has been appointed to serve on the Audit Committee. The appointments are effective immediately and shall expire at the end of the current Board term, which concludes at the 2025 Annual General Meeting.

     

    Dr. Kündig is a distinguished leader in academic medicine, currently serving as Director of the Department of Dermatology at the University Hospital Zurich and Full Professor of Dermatology and Allergology at the University of Zurich. With over three decades of experience spanning clinical care, translational research, and institutional leadership, he brings a unique blend of scientific rigor, operational excellence, and strategic vision. Dr. Kündig’s career is marked by pioneering contributions to immunodermatology, particularly in the development of intralymphatic immunotherapy (ILIT), which has significantly reduced treatment durations for allergy patients. His research group has also advanced preclinical models for cancer immunotherapy and allergen-specific monoclonal antibodies. As a department head, Dr. Kündig has overseen substantial resources and complex clinical operations, leading initiatives in patient-centered care, including the integration of self-help programs to enhance health literacy. Dr. Kündig’s governance experience includes board roles in the Swiss Society for Dermatology & Venereology and the European Dermatology Forum. As well, he is a recipient of the Swiss Technology Award and the Georg-Friedrich Götz Prize. Prof. Kündig received an M.D. from the University of Zürich. In light of Dr. Kündig’s significant academic, scientific, governance, and management roles, the Board believes he is well-qualified to serve as a director of the Company and a member of the Compensation Committee.

     

    Mr. Rademaker is presently responsible for a leading independent Private Equity firm focused on life sciences, logistics, industrial and energy sectors among others with offices in Vancouver, Edmonton, Calgary, and Toronto, directly or indirectly employing more than 7,500 employees and with assets valued in excess of $5 billion. Mr. Rademaker has over 25 years’ experience in the financial industry, covering a multitude of areas and industries, both private and public. These include institutional and retail brokerage, principal trading, equity and debt raising, mergers and acquisitions advice and venture capital as a facilitator and principal investor. Mr. Rademaker started his career in venture capital at the age of 16, working in his father’s firm in Vancouver, British Columbia. At 23 Mr. Rademaker began working on trade desk and was quickly promoted the underwriting group, managing an international trade desk with focus on trading volatility and market making for public companies. During his underwriting years, Mr. Rademaker was responsible for multiple initial public offerings, reverse take overs and mergers related to US, Canadian and international exchanges. Mr. Rademaker later transitioned to become a capital markets leader at a Canadian private equity firm and opened a Canadian office for a European trust company group. Mr. Rademaker has a B.Sc. degree in economics from Simon Fraser University. In light of Mr. Rademaker’s extensive financial, capital markets, and public company experience, the Board believes he is well-qualified to serve as a director of the Company and as a financially sophisticated member of the Audit Committee.

     

    John Simard, President and CEO of XBiotech, commented, “We are excited to welcome Dr. Kündig and Mr. Rademaker to our Board of Directors. I believe they bring deep experience and valuable perspectives that will serve our Company well as we move forward.”

     

    Following these appointments, the Audit Committee will consist of Jan-Paul Waldin, Dr. Peter Libby, and Mr. Rademaker, while the Compensation Committee will consist of Mr. Waldin, Dr. Libby, and Dr. Kündig.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Date: June 24, 2025XBIOTECH INC.
        
        
     By: /s/John Simard
       John Simard
       Chief Executive Officer and President

     

     

    Get the next $XBIT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $XBIT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XBIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XBiotech Pauses Rheumatology program

      AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal interpretation of the findings difficult. XBiotech was planning launch of additional studies in arthritis as well as other areas of rheumatology, including ankylosing spondylitis, which are now on hold while recent findings are evaluated. About 230 subjects with modera

      12/23/24 9:00:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

      AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might po

      6/18/24 11:35:14 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

      AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate we

      1/4/24 9:00:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Simard John

      4 - XBiotech Inc. (0001626878) (Issuer)

      3/19/25 3:03:42 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Simard John

      4 - XBiotech Inc. (0001626878) (Issuer)

      2/4/25 4:53:27 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mckenzie W Thorpe

      4 - XBiotech Inc. (0001626878) (Issuer)

      6/21/24 2:16:44 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    SEC Filings

    See more
    • XBiotech Inc. filed SEC Form 8-K: Leadership Update

      8-K - XBiotech Inc. (0001626878) (Filer)

      6/24/25 5:06:29 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by XBiotech Inc.

      10-Q - XBiotech Inc. (0001626878) (Filer)

      5/14/25 3:55:11 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by XBiotech Inc.

      10-K/A - XBiotech Inc. (0001626878) (Filer)

      4/29/25 3:59:49 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Financials

    Live finance-specific insights

    See more
    • XBiotech Announces Payment of Dividend to Holders of Common Stock

      AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech's balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug

      7/30/21 11:03:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Announces Dividend to Holders of Common Stock

      AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ:XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021. "XBiotech's proven ability to develop highly valued drug candidates, revenue from contract operations, judicious deployment of operating capital, absence of debt, and very significant emerging opportunities in our pipeline, has created the balance sheet flexibility that enables us to provide shareholder

      7/6/21 4:30:00 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:36:43 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:01:48 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:01:06 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care